Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTA... por F. Barata, H. Queiroga, E. Teixeira, T. Almodovar, M. Soares, B. Parente, J.C. Mellidez, P. Alves, A. Antunes

Enlace del recurso

Insulin sensitivity estimates and their longitudinal association with coronary artery disease in type 1 diabetes. Does it matter? por Stefan Mutter, Erika B. Parente, Andrzej S. Januszewski, Johan R. Simonsen, Valma Harjutsalo, Per-Henrik Groop, Alicia J. Jenkins, Lena M. Thorn, the FinnDiane Study Group

Enlace del recurso

Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC) por A. Figueiredo, M.A. Almeida, M.T. Almodovar, P. Alves, A. Araújo, D. Araújo, F. Barata, L. Barradas, A. Barroso, U. Brito, E. Camacho, D. Canário, T. Cardoso, A. Chaves, L. Costa, J. Cunha, J. Duarte, F. Estevinho, M. Felizardo, J.P. Fernandes, L. Ferreira, L. Ferreira, P. Fidalgo, C. Freitas, P. Garrido, N. Gil, D. Hasmucrai, E. Jesus, J.A. Lopes, J.E. de Macedo, A. Meleiro, R. Neveda, F. Nogueira, M. Pantorotto, B. Parente, A. Pego, M. Rocha, J. Roque, C. Santos, J. Saraiva, E. Silva, S. Silva, S. Simões, M. Soares, E. Teixeira, T. Timóteo, V. Hespanhol

Enlace del recurso